Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $20.96, for a total value of $314,400.00. Following the completion of the transaction, the insider owned 334,786 shares in the company, valued at $7,017,114.56. The trade was a 4.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.04, for a total transaction of $300,600.00.
• On Tuesday, March 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.27, for a total transaction of $304,050.00.
• On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.60, for a total transaction of $384,000.00.

Kestra Medical Technologies Trading Down 1.2%

NASDAQ:KMTS opened at $19.59 on Tuesday. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.14 billion, a PE ratio of -4.95 and a beta of 0.82. The firm’s 50 day moving average is $20.65 and its 200 day moving average is $23.86. Kestra Medical Technologies, Ltd. has a 12 month low of $13.25 and a 12 month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The company had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The company’s revenue was up 62.7% on a year-over-year basis. Sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current year.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC purchased a new stake in Kestra Medical Technologies during the fourth quarter valued at about $31,000. Russell Investments Group Ltd. boosted its position in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Kestra Medical Technologies during the third quarter valued at about $48,000. BNP Paribas Financial Markets boosted its position in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the period. Finally, Daiwa Securities Group Inc. purchased a new stake in Kestra Medical Technologies during the fourth quarter valued at about $72,000.

Analyst Ratings Changes

A number of equities research analysts have issued reports on KMTS shares. BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. Finally, The Goldman Sachs Group reduced their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Kestra Medical Technologies presently has a consensus rating of “Hold” and an average target price of $27.40.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.